Eating disorders: an overview of treatment responses and the potential impact of vulnerability genes and endophenotypes

Bibliography

• BULIK CM, REBA L, SIEGA-RIZ AM, REICHBORN-KJENNERUD T: Anorexia nervosa: definition, epidemiology, and cycle of risk. Int. J. Eat. Disord. (2005) 37:S2-S9.
   PubMed Web of Science ®Google Scholar
• GORWOOD P, KIPMAN A, FOULON C: The human genetics of anorexia nervosa. Eur. J. Pharmacol. (2003) 480(1-3):163-170.
   PubMed Web of Science ®Google Scholar
• AMERICAN PSYCHIATRIC ASSOCIATION, DSM-IV: Diagnostic and Statistical Manual of Mental Disorders. 4th Edition, American Psychiatric Association, Washington, DC (1997).
   Google Scholar
• HOEK HW, VAN HOEKEN D: Review of the prevalence and incidence of eating disorders. Int. J. Eat. Disord. (2003) 34(4):383-396.
   PubMed Web of Science ®Google Scholar
• HOEK HW: Incidence, prevalence and mortality of anorexia nervosa and other eating disorders. Curr. Opin. Psychiatry (2006) 19(4):389-394.
   PubMed Web of Science ®Google Scholar
• HUDSON JI, HIRIPI E, POPE HG Jr, KESSLER RC: The prevalence and correlates of eating disorders in the national comorbidity survey replication. Biol. Psychiatry (2007) 61(3):348-358.
   PubMed Web of Science ®Google Scholar
• LUCAS AR, BEARD CM, O'FALLON WM, KURLAND LT: 50-year trends in the incidence of anorexia nervosa in Rochester, Minn: a population-based study. Am. J. Psychiatry (1991) 148(7):917-922.
   PubMed Web of Science ®Google Scholar
• BIRMINGHAM CL, SU J, HLYNSKY JA, GOLDNER EM, GAO M: The mortality rate from anorexia nervosa. Int. J. Eat. Disord. (2005) 38(2):143-146.
   PubMed Web of Science ®Google Scholar
• MILLAR HR, WARDELL F, VYVYAN JP, NAJI SA, PRESCOTT GJ, EAGLES JM: Anorexia nervosa mortality in Northeast Scotland, 1965 – 1999. Am. J. Psychiatry (2005) 162(4):753-757.
   PubMed Web of Science ®Google Scholar
• QUADFLIEG N, FICHTER MM: The course and outcome of bulimia nervosa. Eur. Child Adolesc. Psychiatry (2003) 12(Suppl. 1):I99-109.
   PubMedGoogle Scholar
• AMERICAN PSYCHIATRIC ASSOCIATION: Treatment of patients with eating disorders, third edition. American Psychiatric Association. Am. J. Psychiatry (2006) 163(7 Suppl.):4-54.
   Google Scholar
• LOCK J, LE GRANGE D: Family-based treatment of eating disorders. Int. J. Eat. Disord. (2005) 37:S64-S67.
   PubMed Web of Science ®Google Scholar
• MITCHELL JE, PETERSON CB, MYERS T, WONDERLICH S: Combining pharmacotherapy and psychotherapy in the treatment of patients with eating disorders. Psychiatr. Clin. North Am. (2001) 24(2):315-323.
   PubMed Web of Science ®Google Scholar
• ZHU AJ, WALSH BT: Pharmacologic treatment of eating disorders. Can. J. Psychiatry (2002) 47(3):227-234.
   PubMed Web of Science ®Google Scholar
• ATTIA E, SCHROEDER L: Pharmacologic treatment of anorexia nervosa: where do we go from here? Int. J. Eat. Disord. (2005) 37:S60-S63.
   Web of Science ®Google Scholar
• MITCHELL JE, DE ZWAAN M, ROERIG JL: Drug therapy for patients with eating disorders. Curr. Drug Targets CNS Neurol. Disord. (2003) 2(1):17-29.
   PubMedGoogle Scholar
• DALLY PJ, SARGANT W: A new treatment of anorexia nervosa. BMJ (1960) 1(5188):1770-1773.
   PubMed Web of Science ®Google Scholar
• DALLY PJ, SARGANT W: Treatment and outcome of anorexia nervosa. BMJ (1966) 2(5517):793-795.
   PubMed Web of Science ®Google Scholar
• VANDEREYCKEN W, PIERLOOT R: Pimozide combined with behavior therapy in the short-term treatment of anorexia nervosa. A double-blind placebo-controlled cross-over study. Acta Psychiatr. Scand. (1982) 66(6):445-450.
   PubMed Web of Science ®Google Scholar
• VANDEREYCKEN W: Neuroleptics in the short-term treatment of anorexia nervosa. A double-blind placebo-controlled study with sulpiride. Br. J. Psychiatry (1984) 144:288-292.
   PubMed Web of Science ®Google Scholar
• DUNICAN KC, DELDOTTO D: The role of olanzapine in the treatment of anorexia nervosa. Ann. Pharmacother. (2007) 41(1):111-115.
   PubMed Web of Science ®Google Scholar
• LA VIA MC, GRAY N, KAYE WH: Case reports of olanzapine treatment of anorexia nervosa. Int. J. Eat. Disord. (2000) 27(3):363-366.
   PubMed Web of Science ®Google Scholar
• POWERS PS, SANTANA CA, BANNON YS: Olanzapine in the treatment of anorexia nervosa: an open label trial. Int. J. Eat. Disord. (2002) 32(2):146-154.
   PubMed Web of Science ®Google Scholar
• MONDRATY N, BIRMINGHAM CL, TOUYZ S, SUNDAKOV V, CHAPMAN L, BEUMONT P: Randomized controlled trial of olanzapine in the treatment of cognitions in anorexia nervosa. Aust. Psychiatry (2005) 13(1):72-75.
   PubMedGoogle Scholar
• GROSS HA, EBERT MH, FADEN VB, GOLBERG SC, NEE LE, KAYE WH: A double-blind controlled trial of lithium carbonate primary anorexia nervosa. J. Clin. Psychopharmacol. (1981) 1(6):376-381.
   PubMed Web of Science ®Google Scholar
• LACEY JH, CRISP AH: Hunger, food intake and weight: the impact of clomipramine on a refeeding anorexia nervosa population. Postgrad. Med. J. (1980) 56(S1):79-85.
   PubMed Web of Science ®Google Scholar
• CRISP AH, LACEY JH, CRUTCHFIELD M: Clomipramine and ‘drive’ in people with anorexia nervosa: an in-patient study. Br. J. Psychiatry (1987) 150:355-358.
   PubMed Web of Science ®Google Scholar
• BIEDERMAN J, HERZOG DB, RIVINUS TM et al.: Amitriptyline in the treatment of anorexia nervosa: a double-blind,placebo-controlled study. J. Clin. Psychopharmacol. (1985) 5(1):10-16.
   PubMed Web of Science ®Google Scholar
• HALMI KA, ECKERT E, LADU TJ, COHEN J: Anorexia nervosa. Treatment efficacy of cyproheptadine and amitriptyline. Arch. Gen. Psychiatry (1986) 43(2):177-181.
   PubMed Web of Science ®Google Scholar
• RAY WA, MEREDITH S, THAPA PB, HALL K, MURRAY KT: Cyclic antidepressants and the risk of sudden cardiac death. Clin. Pharmacol. Ther. (2004) 75(3):234-241.
   PubMed Web of Science ®Google Scholar
• GWIRTSMAN HE, GUZE BH, YAGER J, GAINSLEY B: Fluoxetine treatment of anorexia nervosa: an open clinical trial. J. Clin. Psychiatry (1990) 51(9):378-382.
   PubMed Web of Science ®Google Scholar
• KAYE WH, NAGATA T, WELTZIN TE et al.: Double-blind placebo-controlled administration of fluoxetine in restricting- and restricting-purging-type anorexia nervosa. Biol. Psychiatry (2001) 49(7):644-652.
   PubMed Web of Science ®Google Scholar
• SANTONASTASO P, FRIEDERICI S, FAVARO A: Sertraline in the treatment of restricting anorexia nervosa: an open controlled trial. J. Child Adolesc. Psychopharmacol. (2001) 11(2):143-150.
   PubMed Web of Science ®Google Scholar
• FASSINO S, LEOMBRUNI P, DAGA G et al.: Efficacy of citalopram in anorexia nervosa: a pilot study. Eur. Neuropsychopharmacol. (2002) 12(5):453-459.
   PubMed Web of Science ®Google Scholar
• ATTIA E, HAIMAN C, WALSH BT, FLATER SR: Does fluoxetine augment the inpatient treatment of anorexia nervosa? Am. J. Psychiatry (1998) 155(4):548-551.
   PubMed Web of Science ®Google Scholar
• FERGUSON CP, LA VIA MC, CROSSAN PJ, KAYE WH: Are serotonin selective reuptake inhibitors effective in underweight anorexia nervosa? Int. J. Eat. Disord. (1999) 25(1):11-17.
   PubMed Web of Science ®Google Scholar
• BARBARICH NC, MCCONAHA CW, HALMI KA et al.: Use of nutritional supplements to increase the efficacy of fluoxetine in the treatment of anorexia nervosa. Int. J. Eat. Disord. (2004) 35(1):10-15.
   PubMed Web of Science ®Google Scholar
• STROBER M, FREEMAN R, DEANTONIO M, LAMPERT C, DIAMOND J: Does adjunctive fluoxetine influence the post-hospital course of restrictor-type anorexia nervosa? A 24-month prospective, longitudinal followup and comparison with historical controls. Psychopharmacol. Bull. (1997) 33(3):425-431.
   PubMed Web of Science ®Google Scholar
• HOLTKAMP K, KONRAD K, KAISER N et al.: A retrospective study of SSRI treatment in adolescent anorexia nervosa:insufficient evidence for efficacy. J. Psychiatr. Res. (2005) 39(3):303-310.
   PubMed Web of Science ®Google Scholar
• WALSH BT, KAPLAN AS, ATTIA E et al.: Fluoxetine after weight restoration in anorexia nervosa: a randomized controlled trial. JAMA (2006) 295(22):2605-2612.
   PubMed Web of Science ®Google Scholar
• SZMUKLER GI, YOUNG GP, MILLER G, LICHTENSTEIN M, BINNS DS: A controlled trial of cisapride in anorexia nervosa. Int. J. Eat. Disord. (1995) 17(4):347-357.
   PubMed Web of Science ®Google Scholar
• STACHER G, ABATZI-WENZEL TA, WIESNAGROTZKI S et al.: Gastric emptying, body weight and symptoms in primary anorexia nervosa. Long-term effects of cisapride. Br. J. Psychiatry (1993) 162:398-402.
   PubMed Web of Science ®Google Scholar
• GROSS H, EBERT MH, FADEN VB et al.: A double-blind trial of delta 9-tetrahydrocannabinol in primary anorexia nervosa. J. Clin. Psychopharmacol. (1983) 3(3):165-171.
   PubMed Web of Science ®Google Scholar
• POWERS PS, BANNON Y, EUBANKS R, McCORMICK T: Quetiapine in anorexia nervosa patients: an open label outpatient pilot study. Int. J. Eat. Disord. (2007) 40(1):21-26.
   PubMed Web of Science ®Google Scholar
• HALMI KA, ECKERT E, FALK JR: Cyproheptadine for anorexia nervosa. Lancet (1982) 1(8285):1357-1358.
   PubMed Web of Science ®Google Scholar
• WALSH BT, HADIGAN CM, DEVLIN MJ, GLADIS M, ROOSE SP: Long-term outcome of antidepressant treatment for bulimia nervosa. Am. J. Psychiatry (1991) 148(9):1206-1212.
   PubMed Web of Science ®Google Scholar
• McCANN UD, AGRAS WS: Successful treatment of nonpurging bulimia nervosa with desipramine: a double-blind, placebo-controlled study. Am. J. Psychiatry (1990) 147(11):1509-1513.
   PubMed Web of Science ®Google Scholar
• CARRUBA MO, CUZZOLARO M, RIVA L et al.: Efficacy and tolerability of moclobemide in bulimia nervosa: a placebo-controlled trial. Int. Clin. Psychopharmacol. (2001) 16(1):27-32.
   PubMed Web of Science ®Google Scholar
• KENNEDY SH, GOLDBLOOM DS, RALEVSKI E et al.: Is there a role for selective monoamine oxidase inhibitor therapy in bulimia nervosa? A placebo-controlled trial of brofaromine. J. Clin. Psychopharmacol. (1993) 13(6):415-422.
   PubMed Web of Science ®Google Scholar
• KENNEDY SH, PIRAN N, WARSH JJ et al.: A trial of isocarboxazid in the treatment of bulimia nervosa. J. Clin. Psychopharmacol. (1988) 8(6):391-396.
   PubMed Web of Science ®Google Scholar
• HUDSON JI, POPE HG Jr, KECK PE Jr, MCELROY SL: Treatment of bulimia nervosa with trazodone: short-term response and long-term follow-up. Clin. Neuropharmacol. (1989) 12:S38-S46.
   PubMed Web of Science ®Google Scholar
• PEDERSON KJ, ROERIG JL, MITCHELL JE: Towards the pharmacotherapy of eating disorders. Expert Opin. Pharmacother. (2003) 4(10):1659-1678.
   PubMed Web of Science ®Google Scholar
• Fluoxetine Bulimia Nervosa Collaborative Study Group: Fluoxetine in the treatment of bulimia nervosa. A multicenter, placebo-controlled, double-blind trial. Arch. Gen. Psychiatry (1992) 49(2):139-147.
   PubMed Web of Science ®Google Scholar
• WALSH BT, AGRAS WS, DEVLIN MJ et al.: Fluoxetine for bulimia nervosa following poor response to psychotherapy. Am. J. Psychiatry (2000) 157(8):1332-1334.
   PubMed Web of Science ®Google Scholar
• FICHTER MM, KRUGER R, RIEF W, HOLLAND R, DOHNE J: Fluvoxamine in prevention of relapse in bulimia nervosa: effects on eating-specific psychopathology. J. Clin. Psychopharmacol. (1996) 16(1):9-18.
   PubMed Web of Science ®Google Scholar
• ROMANO SJ, HALMI KA, SARKAR NP, KOKE SC, LEE JS: A placebo-controlled study of fluoxetine in continued treatment of bulimia nervosa after successful acute fluoxetine treatment. Am. J. Psychiatry (2002) 159(1):96-102.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN DJ, WILSON MG, ASCROFT RC, AL-BANNA M: Effectiveness of fluoxetine therapy in bulimia nervosa regardless of comorbid depression. Int. J. Eat. Disord. (1999) 25(1):19-27.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN DJ, WILSON MG, THOMPSON VL, POTVIN JH, RAMPEY AH Jr: Long-term fluoxetine treatment of bulimia nervosa. Fluoxetine Bulimia Nervosa Research Group. Br. J. Psychiatry (1995) 166(5):660-666.
   PubMed Web of Science ®Google Scholar
• GOLDBLOOM DS, OLMSTED MP: Pharmacotherapy of bulimia nervosa with fluoxetine: assessment of clinically significant attitudinal change. Am. J. Psychiatry (1993) 150(5):770-774.
   PubMed Web of Science ®Google Scholar
• KNABLE M: Topiramate for bulimia nervosa in epilepsy. Am. J. Psychiatry (2001) 158(2):322-323.
   PubMed Web of Science ®Google Scholar
• NICKEL C, TRITT K, MUEHLBACHER M et al.: Topiramate treatment in bulimia nervosa patients: a randomized, double-blind, placebo-controlled trial. Int. J. Eat. Disord. (2005) 38(4):295-300.
   PubMed Web of Science ®Google Scholar
• HEDGES DW, REIMHERR FW, HOOPES SP et al.: Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, Part 2: improvement in psychiatric measures. J. Clin. Psychiatry (2003) 64(12):1449-1454.
   PubMed Web of Science ®Google Scholar
• FUNG SM, FERRILL MJ: Treatment of bulimia nervosa with ondansetron. Ann. Pharmacother. (2001) 35(10):1270-1273.
   PubMed Web of Science ®Google Scholar
• FARIS PL, KIM SW, MELLER WH et al.: Effect of decreasing afferent vagal activity with ondansetron on symptoms of bulimia nervosa: a randomised, double-blind trial. Lancet (2000) 355(9206):792-797.
   PubMed Web of Science ®Google Scholar
• GELBER D, LEVINE J, BELMAKER RH: Effect of inositol on bulimia nervosa and binge eating. Int. J. Eat. Disord. (2001) 29(3):345-348.
   PubMed Web of Science ®Google Scholar
• MARRAZZI MA, KINZIE J, LUBY ED: A detailed longitudinal analysis on the use of naltrexone in the treatment of bulimia. Int. Clin. Psychopharmacol. (1995) 10(3):173-176.
   PubMed Web of Science ®Google Scholar
• FAHY TA, EISLER I, RUSSELL GF: A placebo-controlled trial of D-fenfluramine in bulimia nervosa. Br. J. Psychiatry (1993) 162:597-603.
   PubMed Web of Science ®Google Scholar
• RUSSELL GF, CHECKLEY SA, FELDMAN J, EISLER I: A controlled trial of D-fenfluramine in bulimia nervosa. Clin. Neuropharmacol. (1988) 11(Suppl. 1):S146-159.
   PubMed Web of Science ®Google Scholar
• HSU LK, CLEMENT L, SANTHOUSE R, JU ES: Treatment of bulimia nervosa with lithium carbonate. A controlled study. J. Nerv. Ment. Dis. (1991) 179(6):351-355.
   PubMed Web of Science ®Google Scholar
• CARTER WP, HUDSON JI, LALONDE JK, PINDYCK L, McELROY SL, POPE HG Jr: Pharmacologic treatment of binge eating disorder. Int. J. Eat. Disord. (2003) 34:S74-88.
   PubMed Web of Science ®Google Scholar
• HUDSON JI, McELROY SL, RAYMOND NC et al.: Fluvoxamine in the treatment of binge-eating disorder: a multicenter placebo-controlled, double-blind trial. Am. J. Psychiatry (1998) 155(12):1756-1762.
   PubMed Web of Science ®Google Scholar
• MCELROY SL, CASUTO LS, NELSON EB et al.: Placebo-controlled trial of sertraline in the treatment of binge eating disorder. Am. J. Psychiatry (2000) 157(6):1004-1006.
   PubMed Web of Science ®Google Scholar
• ARNOLD LM, McELROY SL, HUDSON JI, WELGE JA, BENNETT AJ, KECK PE: A placebo-controlled, randomized trial of fluoxetine in the treatment of binge-eating disorder. J. Clin. Psychiatry (2002) 63(11):1028-1033.
   PubMed Web of Science ®Google Scholar
• McELROY SL, HUDSON JI, MALHOTRA S, WELGE JA, NELSON EB, KECK PE Jr: Citalopram in the treatment of binge-eating disorder: a placebo-controlled trial. J. Clin. Psychiatry (2003) 64(7):807-813.
   PubMed Web of Science ®Google Scholar
• DEVLIN MJ, GOLDFEIN JA, PETKOVA E et al.: Cognitive behavioral therapy and fluoxetine as adjuncts to group behavioral therapy for binge eating disorder. Obes. Res. (2005) 13(6):1077-1088.
   PubMedGoogle Scholar
• PEARLSTEIN T, SPURELL E, HOHLSTEIN LA et al.: A double-blind, placebo-controlled trial of fluvoxamine in binge eating disorder: a high placebo response. Arch. Womens Ment. Health (2003) 6(2):147-151.
   PubMedGoogle Scholar
• MCELROY SL, KOTWAL R, HUDSON JI, NELSON EB, KECK PE: Zonisamide in the treatment of binge-eating disorder: an open-label, prospective trial. J. Clin. Psychiatry (2004) 65(1):50-56.
   PubMed Web of Science ®Google Scholar
• McELROY SL, KOTWAL R, GUERDJIKOVA AI et al.: Zonisamide in the treatment of binge eating disorder with obesity: a randomized controlled trial. J. Clin. Psychiatry (2006) 67(12):1897-1906.
   PubMed Web of Science ®Google Scholar
• SHAPIRA NA, GOLDSMITH TD, MCELROY SL: Treatment of binge-eating disorder with topiramate: a clinical case series. J. Clin. Psychiatry (2000) 61(5):368-372.
   PubMed Web of Science ®Google Scholar
• McELROY SL, ARNOLD LM, SHAPIRA NA et al.: Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial. Am. J. Psychiatry (2003) 160(2):255-261.
   PubMed Web of Science ®Google Scholar
• McELROY SL, SHAPIRA NA, ARNOLD LM et al.: Topiramate in the long-term treatment of binge-eating disorder associated with obesity. J. Clin. Psychiatry (2004) 65(11):1463-1469.
   PubMed Web of Science ®Google Scholar
• McELROY SL, SHAPIRA NA, ARNOLD LM et al.: Topiramate in the long-term treatment of binge-eating disorder associated with obesity. J. Clin. Psychiatry (2004) 65(11):1463-1469.
   PubMed Web of Science ®Google Scholar
• MCELROY SL, HUDSON JI, CAPECE JA et al.; Topiramate Binge Eating Disorder Research Group: Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study. Biol. Psychiatry (2007) 61(9):1039-1048.
   PubMed Web of Science ®Google Scholar
• STUNKARD A, BERKOWITZ R, TANRIKUT C, REISS E, YOUNG L: D-fenfluramine treatment of binge eating disorder. Am. J. Psychiatry (1996) 153(11):1455-1459.
   PubMed Web of Science ®Google Scholar
• APPOLINARIO JC, BACALTCHUK J, SICHIERI R et al.: A randomized, double-blind, placebo-controlled study of sibutramine in the treatment of binge-eating disorder. Arch. Gen. Psychiatry (2003) 60(11):1109-1116.
   PubMed Web of Science ®Google Scholar
• MILANO W, PETRELLA C, CASELLA A, CAPASSO A, CARRINO S, MILANO L: Use of sibutramine, an inhibitor of the reuptake of serotonin and noradrenaline, in the treatment of binge eating disorder: a placebo-controlled study. Adv. Ther. (2005) 22(1):25-31.
   PubMed Web of Science ®Google Scholar
• GOLAY A, LAURENT-JACCARD A, HABICHT F et al.: Effect of orlistat in obese patients with binge eating disorder. Obes. Res. (2005) 13(10):1701-1708.
   PubMedGoogle Scholar
• STEFFEN KJ, ROERIG JL, MITCHELL JE, UPPALA S: Emerging drugs for eating disorder treatment. Expert Opin. Emerg. Drugs. (2006) 11(2):315-336.
   PubMedGoogle Scholar
• KIPMAN A, GORWOOD P, MOUREN-SIMEONI MC, ADES J: Genetic factors in anorexia nervosa. Eur. Psychiatry (1999) 14(4):189-198.
   PubMed Web of Science ®Google Scholar
• LILENFELD LR, KAYE WH, GREENO CG et al.: A controlled family study of anorexia nervosa and bulimia nervosa: psychiatric disorders in first-degree relatives and effects of proband comorbidity. Arch. Gen. Psychiatry (1998) 55(7):603-610.
   PubMed Web of Science ®Google Scholar
• STROBER M, FREEMAN R, LAMPERT C, DIAMOND J, KAYE W: Controlled family study of anorexia nervosa and bulimia nervosa: evidence of shared liability and transmission of partial syndromes. Am. J. Psychiatry (2000) 157(3):393-401.
   PubMed Web of Science ®Google Scholar
• BULIK CM, SULLIVAN PF, KENDLER KS: Heritability of binge-eating and broadly defined bulimia nervosa. Biol. Psychiatry (1998) 44(12):1210-1218.
   PubMed Web of Science ®Google Scholar
• BULIK CM, SULLIVAN PF, WADE TD, KENDLER KS: Twin studies of eating disorders: a review. Int. J. Eat. Disord. (2000) 27(1):1-20.
   PubMed Web of Science ®Google Scholar
• REICHBORN-KJENNERUD T, BULIK CM, KENDLER KS et al.: Gender differences in binge-eating: a population-based twin study. Acta Psychiatr. Scand. (2003) 108(3):196-202.
   PubMed Web of Science ®Google Scholar
• WADE TD, CROSBY RD, MARTIN NG: Use of latent profile analysis to identify eating disorder phenotypes in an adult Australian twin cohort. Arch. Gen. Psychiatry (2006) 63(12):1377-1384.
   PubMed Web of Science ®Google Scholar
• BULIK CM, SULLIVAN PF, TOZZI F, FURBERG H, LICHTENSTEIN P, PEDERSEN NL: Prevalence, heritability, and prospective risk factors for anorexia nervosa. Arch. Gen. Psychiatry (2006) 63(3):305-312.
   PubMed Web of Science ®Google Scholar
• KAYE WH, LILENFELD LR, BERRETTINI WH et al.: A search for susceptibility loci for anorexia nervosa: methods and sample description. Biol. Psychiatry (2000) 47(9):794-803.
   PubMed Web of Science ®Google Scholar
• GRICE DE, HALMI KA, FICHTER MM et al.: Evidence for a susceptibility gene for anorexia nervosa on chromosome 1. Am. J. Hum. Genet. (2002) 70(3):787-792.
   PubMed Web of Science ®Google Scholar
• BERGEN AW, VAN DEN BREE MB, YEAGER M et al.: Candidate genes for anorexia nervosa in the 1p33-36 linkage region: serotonin 1D and delta opioid receptor loci exhibit significant association to anorexia nervosa. Mol. Psychiatry (2003) 8(4):397-406.
   PubMed Web of Science ®Google Scholar
• DEVLIN B, BACANU SA, KLUMP KL, et al.: Linkage analysis of anorexia nervosa incorporating behavioral covariates. Hum. Mol. Genet. (2002) 11(6):689-696.
   PubMed Web of Science ®Google Scholar
• BULIK CM, DEVLIN B, BACANU SA et al.: Significant linkage on chromosome 10p in families with bulimia nervosa. Am. J. Hum. Genet. (2003) 72(1):200-207.
   PubMed Web of Science ®Google Scholar
• BACANU SA, BULIK CM, KLUMP KL et al.: Linkage analysis of anorexia and bulimia nervosa cohorts using selected behavioral phenotypes as quantitative traits or covariates. Am. J. Med. Genet. B Neuropsychiatr. Genet. (2005) 139(1):61-68.
   Google Scholar
• CELLINI E, NACMIAS B, BRECELJ-ANDERLUH M et al.: Case-control and combined family trios analysis of three polymorphisms in the ghrelin gene in European patients with anorexia and bulimia nervosa. Psychiatr. Genet. (2006) 16(2):51-52.
   PubMed Web of Science ®Google Scholar
• ANDO T, KOMAKI G, NARUO T et al.: Possible role of preproghrelin gene polymorphisms in susceptibility to bulimia nervosa. Am. J. Med. Genet. B Neuropsychiatr. Genet. (2006) 141(8):929-934.
   Web of Science ®Google Scholar
• DARDENNES RM, ZIZZAZI P, TOLLE V et al.: Family trios analysis of common polymorphisms in the obestatin/ghrelin, BDNF and AGRP genes in patients with Anorexia nervosa: association with subtype, body-mass index, severity and age of onset. Psychoneuroendocrinology (2007) 32(2):106-113.
   PubMed Web of Science ®Google Scholar
• MONTELEONE P, TORTORELLA A, CASTALDO E, DI FILIPPO C, MAJ M: No association of the Arg51Gln and Leu72Met polymorphisms of the ghrelin gene with anorexia nervosa or bulimia nervosa. Neurosci. Lett. (2006) 398(3):325-327.
   PubMed Web of Science ®Google Scholar
• MONTELEONE P, TORTORELLA A, CASTALDO E, DI FILIPPO C, MAJ M: The Leu72Met polymorphism of the ghrelin gene is significantly associated with binge eating disorder. Psychiatr. Genet. (2007) 17(1):13-16.
   PubMed Web of Science ®Google Scholar
• MIYASAKA K, HOSOYA H, SEKIME A et al.: Association of ghrelin receptor gene polymorphism with bulimia nervosa in a Japanese population. J. Neural Transm. (2006) 113(9):1279-1285.
   PubMed Web of Science ®Google Scholar
• HINNEY A, BORNSCHEUER A, DEPENBUSCH M et al.: No evidence for involvement of the leptin gene in anorexia nervosa, bulimia nervosa, underweight or early onset extreme obesity: identification of two novel mutations in the coding sequence and a novel polymorphism in the leptin gene linked upstream region. Mol. Psychiatry (1998) 3(6):539-543.
   PubMed Web of Science ®Google Scholar
• HINNEY A, FRIEDEL S, REMSCHMIDT H, HEBEBRAND J: Genetic risk factors in eating disorders. Am. J. Pharmacogenom. (2004) 4(4):209-223.
   PubMedGoogle Scholar
• QUITON ND, MEECHAN DW, BROWN K, EASTWOOD H, BLAKEMORE AI: Single nucleotide polymorphisms in the leptin receptor gene: studies in anorexia nervosa. Psychiatr. Genet. (2004) 14(4):191-194.
   PubMed Web of Science ®Google Scholar
• MIKOLAJCZYK E, SMIAROWSKA M, GRZYWACZ A, SAMOCHOWIEC J: Association of eating disorders with catechol-o-methyltransferase gene functional polymorphism. Neuropsychobiology (2006) 54(1):82-86.
   PubMed Web of Science ®Google Scholar
• FRIELING H, ROMER KD, WILHELM J et al.: Association of catecholamine-O-methyltransferase and 5-HTTLPR genotype with eating disorder-related behavior and attitudes in females with eating disorders. Psychiatr. Genet. (2006) 16(5):205-208.
   PubMed Web of Science ®Google Scholar
• ROSENLRANZ K, HINNEY A, ZIEGLER A et al.: Systematic mutation screening of the estrogen receptor β gene in probands of different weight extremes: identification of several genetic variants. J. Clin. Endocrinol. Metab. (1998) 83(12):4524-4527.
   PubMed Web of Science ®Google Scholar
• NILSSON M, NAESSEN S, DAHLMAN I, LINDEN HIRSCHLERG A, GUSTAFSSON JA, DAHLMAN-WRIGHT K: Association of estrogen receptor beta gene polymorphisms with bulimic disease in women. Mol. Psychiatry (2004) 9(1):28-34.
   PubMed Web of Science ®Google Scholar
• EASTWOOD H, BROWN KM, MARKOVIC D, PIERI LF: Variation in the ESR1 and ESR2 genes and genetic susceptibility to anorexia nervosa. Mol. Psychiatry (2002) 7(1):86-89.
   PubMed Web of Science ®Google Scholar
• RIBASES M, GRATACOS M, FERNANDEZ-ARANDA F et al.: Association of BDNF with anorexia, bulimia and age of onset of weight loss in six European populations. Hum. Mol. Genet. (2004) 13(12):1205-1212.
   PubMed Web of Science ®Google Scholar
• MONTELEONE P, ZANARDINI R, TORTORELLA A et al.: The 196G/A (val66met) polymorphism of the BDNF gene is significantly associated with binge eating behavior in women with bulimia nervosa or binge eating disorder. Neurosci. Lett. (2006) 406(1-2):133-137.
   PubMed Web of Science ®Google Scholar
• GRATACOS M, GONZALEZ JR, MERCADER JM, CID RD, URRETAVIZCAYA M, ESTIVILL X: Brain-derived neurotrophic factor Val66Met and psychiatric disorders: meta-analysis of case-control studies confirm association to substance-related disorders, eating disorders, and schizophrenia. Biol. Psychiatry (2007) 61(7):911-922.
   PubMed Web of Science ®Google Scholar
• BROWN KM, BUJAC SR, MANN ET, CAMPBELL DA, STUBBINS MJ, BLUNDELL JE: Further evidence of association of OPRD1 & HTR1D polymorphisms with susceptibility to anorexia nervosa. Biol. Psychiatry (2007) 61(3):367-373.
   PubMed Web of Science ®Google Scholar
• SIEGFRIED Z, KANYAS K, LATZER Y et al.: Association study of cannabinoid receptor gene (CNR1) alleles and anorexia nervosa: differences between restricting and binging/purging subtypes. Am. J. Med. Genet. B Neuropsychiatr. Genet. (2004) 125(1):126-130.
   Google Scholar
• URWIN RE, BENNETTS B, WILCKEN B et al.: Anorexia nervosa (restrictive subtype) is associated with a polymorphism in the novel norepinephrine transporter gene promoter polymorphic region. Mol. Psychiatry (2002) 7(6):652-657.
   PubMed Web of Science ®Google Scholar
• BRUINS-SLOT L, GORWOOD P, BOUVARD M et al.: Lack of association between anorexia nervosa and D3 dopamine receptor gene. Biol. Psychiatry (1998) 43(1):76-78.
   PubMed Web of Science ®Google Scholar
• HINNEY A, SCHNEIDER J, ZIEGLER A et al.: No evidence for involvement of polymorphisms of the dopamine D4 receptor gene in anorexia nervosa, underweight, and obesity. Am. J. Med. Genet. (1999) 88(6):594-597.
   PubMed Web of Science ®Google Scholar
• LEVITAN RD, MASELLIS M, BASILE VS et al.: The dopamine-4 receptor gene associated with binge eating and weight gain in women with seasonal affective disorder: an evolutionary perspective. Biol. Psychiatry (2004) 56(9):665-669.
   PubMed Web of Science ®Google Scholar
• BERGEN AW, YEAGER M, WELCH RA et al.: Association of multiple DRD2 polymorphisms with anorexia nervosa. Neuropsychopharmacology (2005) 30(9):1703-1710.
   PubMed Web of Science ®Google Scholar
• SHINOHARA M, MIZUSHIMA H, HIRANO M et al.: Eating disorders with binge-eating behaviour are associated with the s allele of the 3′-UTR VNTR polymorphism of the dopamine transporter gene. J. Psychiatry Neurosci. (2004) 29(2):134-137.
   PubMed Web of Science ®Google Scholar
• BREWERTON TD: Toward a unified theory of serotonin dysregulation in eating and related disorders. Psychoneuroendocrinology (1995) 20(6):561-590.
   PubMed Web of Science ®Google Scholar
• KAYE W, GENDALL K, STROBER M: Serotonin neuronal function and selective serotonin reuptake inhibitor treatment in anorexia and bulimia nervosa. Biol. Psychiatry (1998) 44(9):825-838.
   PubMed Web of Science ®Google Scholar
• RICCA V, NACMIAS B, BOLDRINI M et al.: Psychopathological traits and 5-HT2A receptor promoter polymorphism (-1438 G/A) in patients suffering from Anorexia Nervosa and Bulimia Nervosa. Neurosci. Lett. (2004) 365(2):92-96.
   PubMed Web of Science ®Google Scholar
• FUENTES JA, LAUZURICA N, HURTADO A et al.: Analysis of the -1438 G/A polymorphism of the 5-HT2A serotonin receptor gene in bulimia nervosa patients with or without a history of anorexia nervosa. Psychiatr. Genet. (2004) 14(2):107-109.
   PubMed Web of Science ®Google Scholar
• BRUCE KR, STEIGER H, JOOBER R, Ng YING KIN NM, ISRAEL M, YOUNG SN: Association of the promoter polymorphism -1438G/A of the 5-HT2A receptor gene with behavioral impulsiveness and serotonin function in women with bulimia nervosa. Am. J. Med. Genet. B Neuropsychiatr. Genet. (2005) 137(1):40-44.
   Google Scholar
• HU X, GIOTAKIS O, LI T, KARWAUTZ A, TREASURE J, COLLIER DA: Association of the 5-HT2c gene with susceptibility and minimum body mass index in anorexia nervosa. Neuroreport (2003) 14(6):781-783.
   PubMed Web of Science ®Google Scholar
• BURNET PW, SMITH KA, COWEN PJ, FAIRBURN CG, HARRISON PJ: Allelic variation of the 5-HT2C receptor (HTR2C) in bulimia nervosa and binge eating disorder. Psychiatr. Genet. (1999) 9(2):101-104.
   PubMed Web of Science ®Google Scholar
• GORWOOD P: Eating disorders, serotonin transporter polymorphisms and potential treatment response. Am. J. Pharmacogenom. (2004) 4(1):9-17.
   PubMedGoogle Scholar
• MONTELEONE P, TORTORELLA A, CASTALDO E, MAJ M: Association of a functional serotonin transporter gene polymorphism with binge eating disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. (2006) 141(1):7-9.
   Google Scholar
• URWIN RE, NUNN KP: Epistatic interaction between the monoamine oxidase A and serotonin transporter genes in anorexia nervosa. Eur. J. Hum. Genet. (2005) 13(3):370-375.
   PubMed Web of Science ®Google Scholar
• BERTELSEN KM, VENKATAKRISHNAN K, VON MOLTKE LL, OBACH RS, GREENBLATT DJ: Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. Drug Metab. Dispos. (2003) 31(3):289-293.
   PubMed Web of Science ®Google Scholar
• STEIMER W, MULLER B, LEUCHT S, KISSLING W: Pharmacogenetics: a new diagnostic tool in the management of antidepressive drug therapy. Clin. Chim. Acta (2001) 308(1-2):33-41.
   PubMedGoogle Scholar
• WANG JH, LIU ZQ, WANG W et al.: Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. Clin. Pharmacol. Ther. (2001) 70(1):42-47.
   PubMed Web of Science ®Google Scholar
• KIRCHHEINER J, NICKCHEN K, BAUER M et al.: Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol. Psychiatry (2004) 9(5):442-473.
   PubMed Web of Science ®Google Scholar
• DORADO P, BERECZ R, PENAS-LLEDO EM, CACERES MC, LLERENA A: Clinical implications of CYP2D6 genetic polymorphism during treatment with antipsychotic drugs. Curr. Drug. Targets (2006) 7(12):1671-1680.
   PubMed Web of Science ®Google Scholar
• YU YW, TSAI SJ, CHEN TJ, LIN CH, HONG CJ: Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol. Psychiatry (2002) 7(10):1115-1119.
   PubMed Web of Science ®Google Scholar
• LEE MS, LEE HY, LEE HJ, RYU SH: Serotonin transporter promoter gene polymorphism and long-term outcome of antidepressant treatment. Psychiatr. Genet. (2004) 14(2):111-115.
   PubMed Web of Science ®Google Scholar
• MATSUSHITA S, SUZUKI K, MURAYAMA M et al.: Serotonin transporter regulatory region polymorphism is associated with anorexia nervosa. Am. J. Med. Genet. B Neuropsychiatr. Genet. (2004) 128(1):114-117.
   Google Scholar
• DAVIS C, LEVITAN RD, KAPLAN AS et al.: Dopamine transporter gene (DAT1) associated with appetite suppression to methylphenidate in a case-control study of binge eating disorder. Neuropsychopharmacology (2007) (In Press).
   Google Scholar
• BULIK CM, BACANU SA, KLUMP KL et al.: Selection of eating-disorder phenotypes for linkage analysis. Am. J. Med. Genet. B Neuropsychiatr. Genet. (2005) 139(1):81-87.
   Google Scholar
• GOTTESMAN II, GOULD TD: The endophenotype concept in psychiatry: etymology and strategic intentions. Am. J. Psychiatry (2003) 160(4):636-645.
   PubMed Web of Science ®Google Scholar
• LENA SM, FIOCCO AJ, LEYENAAR JK: The role of cognitive deficits in the development of eating disorders. Neuropsychol. Rev. (2004) 14:99-113.
   PubMed Web of Science ®Google Scholar
• ROBERTS ME, TCHANTURIA K, STAHL D, SOUTHGATE L, TREASURE J: A systematic review and meta-analysis of set-shifting ability in eating disorders. Psychol. Med. (2007) 30:1-12.
   Google Scholar